# MaxCyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maxcyte

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Website: www.maxcyte.com
- Total disclosed funding: $29M
- Latest round: Series E (Dec 16, 2014)
- Investors on record: 7

## About

Founded in 1998 and based in Maryland, US, MaxCyte, Inc. is a clinical-stage cell therapeutics company with a pipeline of product development partnerships in cell-based therapies. The company was founded by CEO and President Mr. Doug Doerfler. In 2000, the company developed the MaxCyte GT® Scalable Transfection System for cell therapy development and commercialization. In 2003, the company began entering license agreements with developers of human cell therapies to enable the development of novel therapeutic products based on our delivery platform. In April 2019, MaxCyte launched the ExPERT™ technology platform. MaxCyte has raised a total of USD 29.95 million funded by 3 investors, Harbert Growth Partners, Tall Oaks Capital Partners and Intersouth Partners. In March 2016, MaxCyte was listed at London AIM under the symbol MXCT. MaxCyte is registered on NASDAQ under the ticker symbol MXCT. As of March 2021, the company has 65 full-time employees.

The company conducts the discovery and development, manufacturing, and commercialization of cell-based medicines. The product line of the company includes platforms such as ATx, STx and GTx that represent the Flow Electroporation® technology for complex cellular engineering. This technology enables the company's biopharmaceutical partners to advance the development of innovative medicines particularly in cell therapy. The company's cell-engineering platform harnesses the power of the cell to accelerate the development of small molecule drugs, biologics, vaccines, and cell and gene therapies to address a wide array of acute and chronic disease indications. The company's cell-loading technologies use blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company works to develop immune system therapies in a variety of fields, including oncology and cardiology.

As of 2020, the company generated annual revenue of USD 26.17 million.

## Funding rounds

- Series E, Dec 16, 2014, $1.7M — Intersouth Partners
- Series D, Aug 13, 2009, $1.1M — Intersouth Partners, Harbert Management, Masa Life Science
- Series D, Aug 13, 2009, $0.4M — Intersouth Partners, Harbert Management, Masa Life Science
- Series C, Aug 14, 2008, $2.1M — Intersouth Partners, Tall Oaks Capital
- Series B, Oct 19, 2007, $1.2M — Intersouth Partners, Harbert Management, Tall Oaks Capital
- Series B, Nov 23, 2006, $6.7M — Intersouth Partners, Harbert Management, Maryland Department of Business and Economic Development, Masa Life Science, Tall Oaks Capital, Korea Integrated Services, MdBio
- Series B, Apr 3, 2006, $5.2M — Intersouth Partners
- Series B, Mar 24, 2004, $11M — Intersouth Partners, Harbert Management, Tall Oaks Capital

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series B, Series C, Series D, Series E
- Harbert Management (https://capitalatlas.ai/funds/harbert-management) — Series B, Series D
- Tall Oaks Capital (https://capitalatlas.ai/funds/tall-oaks-capital) — Series B, Series C
- Maryland Department of Business and Economic Development — Series B
- Masa Life Science — Series B, Series D
- Korea Integrated Services — Series B
- MdBio — Series B